Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Proposed Sale · 144

Insmed Incorporated

INSMNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Jul 9, 2026Accepted Jul 9, 2026, 4:29 PM EDTFiling CIK 1104506Accession 0001628280-26-047798
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
INSMED INC
Issuer CIK
0001104506
SEC file number
000-30739
Phone
9089779900
Person for whose account securities are to be sold
William Lewis
Relationships to issuer
Officer
Street
700 US Highway 202/206
City
Bridgewater
State / country code
NJ
Postal code
08807

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Common10,6991,256,029216,752,45107/09/2026NASDAQMerrill Lynch

Broker / market maker — proposed row 1, entry 1

Name
Merrill Lynch
Street
1800 K ST NW
Street (continued)
Suite 800
City
Washington
State / country code
DC
Postal code
20006

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
Common07/09/2026Stock Plan ActivityIssuer10,699N07/09/2026n/a

Sales reported in the preceding three months

Sales reported in the preceding three months · 7 reported rows
SellerSecuritySale dateAmount soldGross proceeds
William LewisCommon06/25/202621,3982,210,653
William LewisCommon06/08/20266,515612,576
William LewisCommon06/03/20267,605777,746
William LewisCommon05/18/202625,5642,718,106
William LewisCommon05/13/202613,2831,543,186
William LewisCommon05/04/202610,6991,469,434
William LewisCommon04/16/202610,6991,540,292

Seller — prior-sale row 1, entry 1

Name
William Lewis
Street
700 US Highway 202/206
City
Bridgewater
State / country code
NJ
Postal code
08807

Seller — prior-sale row 2, entry 1

Name
William Lewis
Street
700 US Highway 202/206
City
Bridgewater
State / country code
NJ
Postal code
08807

Seller — prior-sale row 3, entry 1

Name
William Lewis
Street
700 US Highway 202/206
City
Bridgewater
State / country code
NJ
Postal code
08807

Seller — prior-sale row 4, entry 1

Name
William Lewis
Street
700 US Highway 202/206
City
Bridgewater
State / country code
NJ
Postal code
08807

Seller — prior-sale row 5, entry 1

Name
William Lewis
Street
700 US Highway 202/206
City
Bridgewater
State / country code
NJ
Postal code
08807

Seller — prior-sale row 6, entry 1

Name
William Lewis
Street
700 US Highway 202/206
City
Bridgewater
State / country code
NJ
Postal code
08807

Seller — prior-sale row 7, entry 1

Name
William Lewis
Street
700 US Highway 202/206
City
Bridgewater
State / country code
NJ
Postal code
08807

Prior-sale reporting

Nothing to report for the preceding three months
N

Notice signature

Notice date
07/09/2026
Signed
William Lewis
Plan adoption dates
09/04/2025

Company context

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines - including two approved therapies to treat chronic, debilitating lung diseases - as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.

Current securities

Recent company filings

  1. Results of Operations and Financial ConditionOct 29, 2026
  2. 10-Q filingOct 29, 2026
  3. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 20, 2026
  4. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 5, 2026
  5. 4 filingSep 11, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.